Inactive· since Feb 17, 2026
- 68
- days it ran
- 0
- relaunches
- 209,309
- EU reach
Ad copy
This review summarizes how GLP-1 and dual GIP/GLP-1 receptor agonists act at the cellular level and their therapeutic applications in metabolic diseases like type 2 diabetes and obesity, highlighting advances in incretin-based treatments. Read the article in Frontiers in Endocrinology, a journal with an Impact Factor of 4.6 and CiteScore of 7.4 ⬇️
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are two incretins that bind to their respective receptors and activate...
LEARN MORELike this ad? Make it yours.
Crush rebuilds this exact creative around your product — your brand, your colors, your offer — in about a minute.
